Sophie L. Gray-Gaillard

Sophie L. Gray-Gaillard

Auto-generated profile, based on publicly available information

Sophie L. Gray-Gaillard

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
MGMarie Samanovic Golden
Marie Samanovic Golden
ACAmber R. Cornelius
Amber R. Cornelius
SGSophie L. Gray-Gaillard
Sophie L. Gray-Gaillard
JAJoseph Richard Allen
Joseph Richard Allen
TKTrishala Karmacharya
Trishala Karmacharya
RHRamin Sedaghat Herati
Ramin Sedaghat Herati
The use of coronavirus disease 2019 (COVID-19) vaccines will play the major role in helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have resulted in robust humoral responses and protective efficacy in human trials, but efficacy trials excluded individuals with a prior diagnosis of COVID-19. As a result, little is known about how immune responses induced by mRNA vaccines differ in individuals who recovered from COVID-19. Here, we evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19. Consistent with prior studies of mRNA vaccines, we observed robust cytotoxic CD8 + T cell responses in both cohorts after the second dose. Furthermore, SARS-CoV-2–naive individuals had progressive increases in humoral and antigen-specific antibody-secreting cell (ASC) responses after each dose of vaccine, whereas SARS-CoV-2–experienced individuals demonstrated strong humoral and antigen-specific ASC responses to the first dose but these responses were not further enhanced after the second dose of the vaccine at the time points studied. Together, these data highlight the relevance of immunological history for understanding vaccine immune responses and may have implications for personalizing mRNA vaccination regimens used to prevent COVID-19, including for the deployment of booster shots.

9 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MSMarie I. Samanovic
Marie I. Samanovic
ACAmber R. Cornelius
Amber R. Cornelius
JWJimmy P. Wilson
Jimmy P. Wilson
TKTrishala Karmacharya
Trishala Karmacharya
SGSophie L. Gray-Gaillard
Sophie L. Gray-Gaillard
MTMichael Tuen
Michael Tuen
The use of COVID-19 vaccines will play the major role in helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have resulted in robust humoral responses and protective efficacy in human trials, but efficacy trials excluded individuals with a prior diagnosis of COVID-19. As a result, little is known about how immune responses induced by mRNA vaccines differ in individuals who recovered from COVID-19. Here, we evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who recovered from COVID-19, compared to 21 adults who did not have prior COVID-19 diagnosis. Consistent with prior studies of mRNA vaccines, we observed robust cytotoxic CD8 + T cell responses in both cohorts following the second dose. Furthermore, SARS-CoV-2-naive individuals had progressive increases in humoral and antigen-specific antibody-secreting cell (ASC) responses following each dose of vaccine, whereas SARS-CoV-2-experienced individuals demonstrated strong humoral and antigen-specific ASC responses to the first dose but muted responses to the second dose of the vaccine at the time points studied. Together, these data highlight the relevance of immunological history for understanding vaccine immune responses and may have significant implications for personalizing mRNA vaccination regimens used to prevent COVID-19, including booster shots. One Sentence Summary: Prior history of COVID-19 affects adaptive immune responses to mRNA vaccination.

15 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MGMarie Samanovic Golden
Marie Samanovic Golden
AOAaron L. Oom
Aaron L. Oom
ACAmber R. Cornelius
Amber R. Cornelius
SGSophie L. Gray-Gaillard
Sophie L. Gray-Gaillard
TKTrishala Karmacharya
Trishala Karmacharya
MMMark J. Mulligan
Mark J. Mulligan
Around the world, rollout of COVID-19 vaccines has been used as a strategy to end COVID-19-related restrictions and the pandemic. Several COVID-19 vaccine platforms have successfully protected against severe SARS-CoV-2 infection and subsequent deaths. Here, we compared humoral and cellular immunity in response to either infection or vaccination. We examined SARS-CoV-2 spike-specific immune responses from Pfizer/BioNTech BNT162b2, Moderna mRNA-1273, Janssen Ad26.COV2.S, and SARS-CoV-2 infection approximately 4 months post-exposure or vaccination. We found that these three vaccines all generate relatively similar immune responses and elicit a stronger response than natural infection. However, antibody responses to recent viral variants are diminished across all groups. The similarity of immune responses from the three vaccines studied here is an important finding in maximizing global protection as vaccination campaigns continue.

21 June 2024 in Science Immunology
Verified
Journal Article
Closed access
SGSophie L. Gray-Gaillard
Sophie L. Gray-Gaillard
SSSabrina M. Solis
Sabrina M. Solis
HCHan M. Chen
Han M. Chen
CMClarice Monteiro
Clarice Monteiro
GCGrace Ciabattoni
Grace Ciabattoni
RHRamin Sedaghat Herati
Ramin Sedaghat Herati
Memory CD4 T cells are critical to human immunity, yet it is unclear whether viral inflammation during memory formation has long-term consequences. Here, we compared transcriptional and epigenetic landscapes of Spike (S)–specific memory CD4 T cells in 24 individuals whose first exposure to S was via SARS-CoV-2 infection or mRNA vaccination. Nearly 2 years after memory formation, S-specific CD4 T cells established by infection remained enriched for transcripts related to cytotoxicity and for interferon-stimulated genes, likely because of a chromatin accessibility landscape altered by inflammation. Moreover, S-specific CD4 T cells primed by infection had reduced proliferative capacity in vitro relative to vaccine-primed cells. Furthermore, the transcriptional state of S-specific memory CD4 T cells was minimally altered by booster immunization and/or breakthrough infection. Thus, infection-associated inflammation durably imprints CD4 T cell memory, which affects the function of these cells and may have consequences for long-term immunity.

1 January 2021 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
ABAlexander T. Baugh
Alexander T. Baugh
SGSophie L. Gray-Gaillard
Sophie L. Gray-Gaillard

16 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SGSophie L. Gray-Gaillard
Sophie L. Gray-Gaillard
SSSabrina Solis
Sabrina Solis
HCHan M. Chen
Han M. Chen
CMClarice Monteiro
Clarice Monteiro
GCGrace Ciabattoni
Grace Ciabattoni
RHRamin Sedaghat Herati
Ramin Sedaghat Herati
Summary: Adaptive immune responses are induced by vaccination and infection, yet little is known about how CD4+ T cell memory differs when primed in these two contexts. Notably, viral infection is generally associated with higher levels of systemic inflammation than is vaccination. To assess whether the inflammatory milieu at the time of CD4+ T cell priming has long-term effects on memory, we compared Spike-specific memory CD4+ T cells in 22 individuals around the time of the participants’ third SARS-CoV-2 mRNA vaccination, with stratification by whether the participants’ first exposure to Spike was via virus or mRNA vaccine. Multimodal single-cell profiling of Spike-specific CD4+ T cells revealed 755 differentially expressed genes that distinguished infection- and vaccine-primed memory CD4+ T cells. Spike-specific CD4+ T cells from infection-primed individuals had strong enrichment for cytotoxicity and interferon signaling genes, whereas Spike-specific CD4+ T cells from vaccine-primed individuals were enriched for proliferative pathways by gene set enrichment analysis. Moreover, Spike-specific memory CD4+ T cells established by infection had distinct epigenetic landscapes driven by enrichment of IRF-family transcription factors, relative to T cells established by mRNA vaccination. This transcriptional imprint was minimally altered following subsequent mRNA vaccination or breakthrough infection, reflecting the strong bias induced by the inflammatory environment during initial memory differentiation. Together, these data suggest that the inflammatory context during CD4+ T cell priming is durably imprinted in the memory state at transcriptional and epigenetic levels, which has implications for personalization of vaccination based on prior infection history. One Sentence Summary: SARS-CoV-2 infection versus SARS-CoV-2 mRNA vaccination prime durable transcriptionally and epigenetically distinct Spike-specific CD4+ T cell memory landscapes.